CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED
Get an alert when CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-08-29 (in 3mo)
Last made up 2025-08-15
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£3B
0% vs 2023
Employees
0
Average over period
Profit before tax
£0
+100% vs 2023
Name history
Renamed 2 times since incorporation
- CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED 2011-09-01 → present
- CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 1996-08-22 → 2011-09-01
- INTERCEDE 1186 LIMITED 1996-08-05 → 1996-08-22
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | -£1,000,000 | £0 | |
| Net profit | -£1,000,000 | £0 | |
| Cash | — | — | |
| Total assets less current liabilities | — | — | |
| Net assets | £3,497,000,000 | £3,497,000,000 | |
| Equity | £3,497,000,000 | £3,497,000,000 | |
| Average employees | 0 | 0 | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Gearing (liabilities / total assets) | 0.0% | 0.0% |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED · parent
- MedImmune Limited 100%
- Optein, Inc. 100%
Significant events
- “No subsequent events having material impact on the Financial Statements were identified after the balance sheet date.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 33 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| JOHNSTONE, Camilla Jane | Secretary | 2019-09-06 | — | — |
| BOWDEN, Matthew Shaun | Director | 2019-02-27 | Dec 1977 | British |
| COLLINS, Iain Alistair | Director | 2017-05-31 | Dec 1970 | British |
| TATTERSALL, Hannah Victoria | Director | 2025-05-01 | Jul 1987 | British |
Show 33 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CONACHER, Matthew Ian | Secretary | 2017-03-16 | 2019-09-06 |
| HOSKINS, Justin Wilbert | Secretary | 2005-03-31 | 2006-06-30 |
| KEMP, Adrian Charles Noel | Secretary | 2009-01-01 | 2017-03-16 |
| MELLETT, Diane | Secretary | 1997-12-12 | 2005-03-31 |
| MUSKER, Graeme Harold Rankine | Secretary | 2006-06-30 | 2008-12-31 |
| NIXON, Anthony Michael | Secretary | 1996-08-22 | 1997-12-12 |
| MITRE SECRETARIES LIMITED | Corporate Nominee Secretary | 1996-08-05 | 1996-08-22 |
| ASTON, John Christopher | Director | 1996-10-18 | 2006-06-30 |
| ASTON, Roger | Director | 1996-12-20 | 1997-12-31 |
| BICKER, Uwe, Professor | Director | 1999-02-06 | 2006-02-03 |
| BRIMICOMBE, Ian Martin David | Director | 2006-06-22 | 2017-05-31 |
| BROWN, John Robert, Dr | Director | 2005-09-12 | 2006-06-30 |
| CHAMBRE, Peter Alan | Director | 2002-04-08 | 2006-06-30 |
| CHISWELL, David | Director | 1996-08-22 | 2002-03-31 |
| CUMMING, Alistair Cameron David | Director | 1998-03-01 | 1998-11-29 |
| FOGHT, James Loren | Director | 1996-12-20 | 2003-02-07 |
| GARLAND, Peter Bryan, Professor | Director | 1996-09-10 | 2004-01-30 |
| GLOVER, David Roy, Doctor | Director | 1997-07-11 | 2005-02-04 |
| GRADY, Shaun Francis | Director | 2006-06-22 | 2009-04-06 |
| JACKSON-TURNER, Katie Louise | Director | 2017-03-16 | 2019-02-27 |
| JOHNSON, Kevin Stuart, Dr | Director | 1997-07-11 | 2003-06-19 |
| KEMP, Adrian Charles Noel | Director | 2006-06-22 | 2025-05-01 |
| KLUG, Aaron, Professor Sir | Director | 1996-12-20 | 2006-02-03 |
| MARSHALL, Christopher John | Director | 2004-09-24 | 2006-06-30 |
| MELLETT, Diane | Director | 2005-02-04 | 2006-06-30 |
| MUSKER, Graeme Harold Rankine | Director | 2006-06-22 | 2008-12-31 |
| NICHOLSON, Paul Anthony, Doctor | Director | 1999-02-06 | 2006-06-30 |
| REEVES, Barbara | Nominee Director | 1996-08-05 | 1996-08-22 |
| RINGROSE, Peter Stuart, Doctor | Director | 2003-02-10 | 2006-06-30 |
| STAVLING, Ake Bo Tage | Director | 2002-12-02 | 2006-06-30 |
| STOCKER, John Wilcox, Doctor | Director | 1996-12-20 | 2006-06-30 |
| WEISBROD, Stuart T | Director | 1996-12-20 | 1998-09-30 |
| WINDMILL, Robert John | Nominee Director | 1996-08-05 | 1996-08-22 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Astrazeneca Treasury Limited | Corporate entity | Shares 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 489 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-11-27 MA Memorandum articles
- 2024-11-27 RESOLUTIONS Resolution
- 2024-11-20 CC04 Statement of companys objects
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-08-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-02 | AA | accounts | Accounts with accounts type full | |
| 2025-05-02 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-11-27 | MA | incorporation | Memorandum articles | |
| 2024-11-27 | RESOLUTIONS | resolution | Resolution | |
| 2024-11-20 | CC04 | change-of-constitution | Statement of companys objects | |
| 2024-08-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-05-28 | AA | accounts | Accounts with accounts type full | |
| 2023-10-25 | SH01 | capital | Capital allotment shares | |
| 2023-08-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-03 | AA | accounts | Accounts with accounts type full | |
| 2022-08-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-16 | CH01 | officers | Change person director company with change date | |
| 2022-08-04 | AA | accounts | Accounts with accounts type full | |
| 2021-12-06 | CH01 | officers | Change person director company with change date | |
| 2021-08-27 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2021-08-06 | AA | accounts | Accounts with accounts type full | |
| 2020-12-19 | AA | accounts | Accounts with accounts type full | |
| 2020-11-11 | CH01 | officers | Change person director company with change date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
0%
£3,497,000,000 £3,497,000,000
-
Employees
—
Not reported
-
Profit before tax
+100%
-£1,000,000 £0
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers